Company intelligence / Profile preview

Aisling Capital

New York, New York, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Aisling Capital is an active healthcare and life science-focused private equity and venture capital firm investing in companies developing and commercializing novel therapeutics, medical technologies, and biopharmaceutical outsourcing services. It does not itself run clinical-stage development programs, but rather invests in companies that do so, with a focus on genomically defined cancers, migraines, food allergies, and broader biopharma innovation.

Industry: Investors

Beyond the preview

Go deeper on Aisling Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aisling Capital.

Explore the full profile